Adicet Bio

ACETPre-clinical

Redwood City, United Statesadicetbio.com

Adicet Bio is focused on delivering best-in-class, allogeneic gamma delta T cell therapies, offering a potentially superior alternative to traditional alpha beta CAR-T. Its proprietary platform harnesses the innate tissue-homing, MHC-independent tumor recognition, and favorable safety profile of gamma delta 1 T cells to target both solid tumors and autoimmune diseases. The company is publicly traded and is advancing its lead program, prula-cel, through clinical development with a focus on achieving key milestones in 2026.

Market Cap

$466.8M

Focus

Cell & Gene Therapy

ACET · Stock Price

USD 48.64114.88 (-70.25%)

Historical price data

AI Company Overview

Technology Platform

A proprietary platform for engineering allogeneic gamma delta 1 T cells, leveraging their innate tissue-homing, MHC-independent tumor recognition, and dual adaptive/innate immune functions to create off-the-shelf cell therapies.

Opportunities

The recent validation of CAR-T therapy in autoimmune diseases opens a massive new market.

Adicet's off-the-shelf, gamma delta T cell approach could capture significant value by offering a safer, more convenient, and potentially more effective therapy than autologous alternatives.

Success in autoimmune could also de-risk and fund the platform's application in the enormous solid tumor oncology market.

Risk Factors

The novel gamma delta T cell technology is unproven in late-stage trials.

The company faces clinical, regulatory, and manufacturing risks inherent in cell therapy development.

As a pre-revenue firm, it is dependent on capital markets for funding, and competition in both autoimmune and allogeneic cell therapy is intensifying rapidly.

Competitive Landscape

Adicet competes with autologous CAR-T developers in autoimmune (e.g., Cabaletta, Kyverna) and allogeneic cell therapy companies in oncology (e.g., Allogene, CRISPR). Its key differentiation is the gamma delta 1 T cell platform, which offers potential advantages in safety (low CRS/ICANS), tissue homing for solid tumors/organs, and the convenience of an off-the-shelf product.